NOW FDA-APPROVED

AVAILABLE OCTOBER 2018

Introducing the first and only anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

Sign up to get news and updates for Qbrexza.
All fields are required unless otherwise noted.

Please include NPI Number or Specialty and Practice Address

OR

Practice Address

By checking this box and clicking and "KEEP ME IN THE KNOW", you agree to disclose your personal information to Dermira, Inc., and to be contacted by Dermira and their agents by direct mail, email, telephone, and text message (including autodialed and prerecorded calls and messages) for marketing purposes regarding products, services, market research, site updates, and other information related to excessive underarm sweating and Dermira products and services. You also authorize Dermira to use and disclose your personal information in accordance with Dermira's Privacy Statement. For more information about Dermira's privacy practices please view Dermira's Privacy Statement. You may choose to no longer receive further communications from Dermira by following the unsubscribe instructions on the communication.

Please complete the form before submitting.

We’re sorry, but due to technical difficulties, your submission didn't go through. Please try again later.

Your information has been sent!

Thank you for registering to stay up-to-date with Qbrexza.